The peptide market
doubles by 2035.
The market is growing quickly.
Global peptide therapeutics market
USD, by year. 2025 is reported. 2026 through 2035 compound the reported 6.8% CAGR.
What’s in the pipeline.
Over $7 billion has flowed into peptide R&D from public and private sources. Two hundred-plus companies are active, from Novo Nordisk and Eli Lilly to Apellis, Takeda, Zealand Pharma, and BioLineRx.
Where the growth concentrates.
The headline number is 6.8%. Two segments run three to four times faster.
CAGR by segment, through 2035
Compound annual growth rate. Reported figures, not extrapolation.
$84.2B in 2025 to $162.4B in 2035.
The fastest-growing peptide type.
The fastest-growing therapeutic area.
How the market is built.
By type.
Medium-sized peptides hold the dominant share. Small peptides grow fastest at 20% CAGR.
By route.
Subcutaneous is the majority route today. Topical has significant growth ahead. Oral formulations remove the needle and rewrite adherence.
By therapeutic area.
Metabolic disease anchors the market. GLP-1s for diabetes and obesity carry it. Gastrointestinal peptides grow fastest at 25% CAGR. Cancer and autoimmune follow.
By geography.
North America leads in revenue. Asia-Pacific grows faster. Latin America will continue to grow as well.